- Home
- IZEA vs BCAB Comparison
IZEA vs BCAB Comparison
Compare IZEA & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IZEA
- BCAB
- Stock Information
- Founded
- IZEA 2006
- BCAB 2007
- Country
- IZEA United States
- BCAB United States
- Employees
- IZEA N/A
- BCAB N/A
- Industry
- IZEA Advertising
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- IZEA Consumer Discretionary
- BCAB Health Care
- Exchange
- IZEA Nasdaq
- BCAB Nasdaq
- Market Cap
- IZEA 29.1M
- BCAB 27.0M
- IPO Year
- IZEA N/A
- BCAB 2020
- Fundamental
- Price
- IZEA $1.77
- BCAB $0.38
- Analyst Decision
- IZEA
- BCAB Buy
- Analyst Count
- IZEA 0
- BCAB 2
- Target Price
- IZEA N/A
- BCAB $1.00
- AVG Volume (30 Days)
- IZEA 31.7K
- BCAB 525.8K
- Earning Date
- IZEA 05-14-2025
- BCAB 05-13-2025
- Dividend Yield
- IZEA N/A
- BCAB N/A
- EPS Growth
- IZEA N/A
- BCAB N/A
- EPS
- IZEA N/A
- BCAB N/A
- Revenue
- IZEA $35,881,010.00
- BCAB $11,000,000.00
- Revenue This Year
- IZEA $22.24
- BCAB N/A
- Revenue Next Year
- IZEA N/A
- BCAB N/A
- P/E Ratio
- IZEA N/A
- BCAB N/A
- Revenue Growth
- IZEA N/A
- BCAB N/A
- 52 Week Low
- IZEA $1.68
- BCAB $0.24
- 52 Week High
- IZEA $3.60
- BCAB $3.53
- Technical
- Relative Strength Index (RSI)
- IZEA 32.56
- BCAB 60.29
- Support Level
- IZEA $1.68
- BCAB $0.30
- Resistance Level
- IZEA $1.80
- BCAB $0.34
- Average True Range (ATR)
- IZEA 0.09
- BCAB 0.04
- MACD
- IZEA 0.01
- BCAB 0.01
- Stochastic Oscillator
- IZEA 25.00
- BCAB 92.85
About IZEA IZEA Worldwide Inc.
IZEA Worldwide Inc offers solutions that range from creator agency services to creator technologies to a marketplace that connects marketers with creators. The Company provides value through managing custom content workflow, creator search and targeting, bidding, analytics, and payment processing. The company also enables creators to monetize their content, creativity, and influence through brands and marketers. The company compensates these creators for producing content, such as long and short-form text, videos, photos, status updates, and illustrations, for marketers or distributing such content on behalf of marketers through their websites, blogs, and social media channels.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.